Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

The Lancet Oncology

Additional follow-up of the IMspire150 trial showed that overall survival was not significantly improved with atezolizumab, vemurafenib, and cobimetinib compared with placebo, vemurafenib, and